PPARgamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.
Zinman
Bernard
B
Division of Endocrinology and Metabolism, Department of Medicine, University of Toronto and Samuel Lunenfeld Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada.